Here, we report the formal clinical proof-of-concept, dose-finding phase II global clinical trial in Europe and Asia of namilumab in patients with RA with either an inadequate response to background methotrexate (MTX-IR) or an inadequate response to an anti-tumour necrosis factor (TNF) biologic therapy (TNF-IR). Here, TNF is linked to rheumatoid arthritis.